Prime Medicine presents Wilson disease gene-editing trial plans, targets initial data in 2027
PRME•Prime Medicine expects initial clinical data in 2027 for PM577a in Wilson disease and PM647 in alpha-1 antitrypsin deficiency. The PM577a trial has begun, and PM647 received investigational new drug clearance.
1. Pipeline updates
Prime Medicine said its PM577a clinical trial for Wilson disease has begun and it expects initial clinical data in 2027. The company also expects initial data in 2027 for PM647 in alpha-1 antitrypsin deficiency, which has received investigational new drug clearance.
2. Other programs
Prime Medicine plans to submit a biologics license application for PM359 in chronic granulomatous disease in 2027, subject to final alignment with the FDA. It plans to use its liver-targeted delivery platform for follow-on Wilson disease programs addressing additional mutations and is targeting further strategic partnerships to accelerate pipeline development and bolster financial resources.
